Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Down 20.0% in December

Minerva Neurosciences, Inc. (NASDAQ:NERV) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 7,600 shares, a drop of 20.0% from the November 30th total of 9,500 shares. Based on an average daily trading volume, of 24,000 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are short sold.

Analyst Ratings Changes

NERV has been the subject of several recent research reports. StockNews.com started coverage on Minerva Neurosciences in a report on Saturday. They issued a “sell” rating for the company. HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Stock Performance

NASDAQ NERV traded down $0.07 during trading on Friday, reaching $2.26. 28,172 shares of the company traded hands, compared to its average volume of 50,551. Minerva Neurosciences has a 1-year low of $2.06 and a 1-year high of $13.49. The stock’s 50 day moving average price is $2.28 and its two-hundred day moving average price is $2.70. The company has a market cap of $15.80 million, a price-to-earnings ratio of -5.14 and a beta of 0.11.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.